Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: There were nearly 1,000 drug-related deaths in Scotland last year. Correct, there were 934 registered in 2017. The UK has the highest death rate in the EU from drugs. Estonia had the highest rate of drug-related deaths per million people aged 15 to 64 in the EU, based on research using data from 2015 and 2016. The UK placed joint-third alongside Ireland. Scotland's drug-related death rate is the highest in the EU. Correct if you compare Scotland to a league table of EU sovereign countries. This is based on a comparison of the drug-related death rate per million people aged 15 to 64 in 2015 and 2016. Claim 1 of 4 Claim: Scotland's drug-related death rate is the highest in the EU.

Ex Output:
Correct if you compare Scotland to a league table of EU sovereign countries. This is based on a comparison of the drug-related death rate per million people aged 15 to 64 in 2015 and 2016.

Ex Input:
Paragraph: A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville The GlaxoSmithKline Plc vaccine Rotarix fights infection with the rotavirus, which causes about 55,000 hospitalizations in U.S. children each year and kills more than 600,000 children worldwide, mostly in developing countries. Rotarix already is approved in more than 100 other countries throughout the world. The vaccine competes with Merck & Co Inc's rotavirus vaccine called RotaTeq. Without vaccination, nearly every child in the United States likely would be infected at least once with rotavirus by age five, the Food and Drug Administration said. In studies of more than 24,000 infants, Rotarix prevented severe and mild cases of rotavirus-caused diarrhea and vomiting during the first two years of life. "This vaccine provides another option to combat and reduce a potentially severe illness that affects so many children," Dr. Jesse Goodman, director of the FDA's Center for Biologics Evaluation and Research, said in a statement announcing the Rotarix approval. The most common reactions reported during clinical trials were fussiness, irritability, cough, runny nose, fever, loss of appetite and vomiting, the FDA said. An earlier oral rotavirus vaccine sold by Wyeth was pulled from the market in 1999 after it was linked to a rare, life-threatening type of bowel obstruction known as intussusception. In a Glaxo study of more than 63,000 infants, there was no increase in the problem compared with a placebo. Higher rates of convulsion and pneumonia-related deaths were seen in Rotarix patients in that study but not in other Glaxo trials. "Although the FDA has concluded that the available data do not establish that these events are related to the vaccine, the agency has requested the manufacturer to conduct post-marketing safety studies involving more than 40,000 infants to provide additional safety information," the FDA said. Glaxo said Rotarix "will offer protection against the most commonly circulating rotavirus types in the U.S. and allow infants to complete the vaccination series by four months of age." Rotarix, which is a liquid, is given in two doses to infants from six to 24 weeks of age, the FDA said. Merck's RotaTeq vaccine is administered in three doses from ages six weeks to 32 weeks. Sales of Rotarix were $182 million in 2007 and are expected to rise with approval in the large U.S. market. The vaccine will be commercially available in the United States in the second half of the year, Glaxo said. Also on Thursday, researchers reported that Rotarix provided protection for up to two years in a study of infants from 10 Latin American countries. The Glaxo-funded trial of more than 15,000 infants found severe diarrhea from rotavirus in 0.4 percent of children given the vaccine, compared with 2.3 percent in the placebo group. Results were published in the Lancet medical journal. The arrival of a new generation of oral vaccines against the disease has been welcomed by health-care workers, but some experts caution against assuming the vaccines will work equally well in all countries. In a commentary in the Lancet, Australian pediatric experts Keith Grimwood and Carl Kirkwood noted Rotarix was more effective in European trials than in middle-income Latin American countries. The World Health Organization "is awaiting efficacy data from low-income countries of Africa and Asia, where much greater strain diversity exists and where 413,000 deaths occur every year compared with 15,000 in Latin America and 200 in Europe," Grimwood and Kirkwood wrote. Claim: Glaxo wins FDA clearance for rotavirus vaccine.

Ex Output:
A second oral vaccine to prevent a leading cause of severe diarrhea in infants won approval from U.S. health officials on Thursday.

Ex Input:
Paragraph: An image that purports to show a screengrab from a medical journal wasfeatured on a tweet that gained traction on January 15 2020.The tweetcontains a capture of this citation:It says:Hormone replacement therapy has many nicknames among transfeminine people, including titty pills, titty skittles, smartitties, chicklets, anticistamines, mammary mints, life savers, tit tacs, breast mints, femme&m's, antiboyotics, trans-mission fluid, and the Notorious H.R.T."oh fuck this was in an actual medical journal I'm gonna cry lmao," the user wrote.While it is legitimate, many of the users sharing it may not be aware of the context behind it. The citation was included in an article published by the McGill Journal of Law and Health, a publication covering healthcare-related law. The story itself is a first-person account by activist Florence Ashley regarding their experience seeking medical care both pre-and post-gender transition.Their listing of the nicknames for hormone replacement therapy (HRT) appears alongside a passage covering the temporary effects from stopping the treatment prior to reassignment surgery:I had to stop taking the hormones three weeks before surgery, give or take a few days. I was ill-prepared for this endeavour. Because hormones regulate emotions, amongst many other things, changes in hormonal regimen can have a heavy impact on mood stability and mental health. In my case, the fluctuations were large enough that I had to raise my dosage of antidepressant.A few months after surgery, my reflection in the mirror elicited an emotional reaction I had not yet grown accustomed to. After over a year on hormone replacement therapy, my body had changed in ways that finally began feeling comfortable. After decades of discontent, I was finally feeling at home in what I had previously described as a flesh prison. It had only taken a few weeks without hormones to lose what I estimated as six months of progress, noticeable in terms of fat redistribution, breast tissue loss, and changes to sexual functioning. The mirror served me a cruel reminder of this loss of self.In their paper, Ashley argues that current regulations covering disclosure of information between medical providers and transgender patients rely "on overly narrow conceptions of informed consent and underestimates the role that communal knowledge should play in health care."Their own surgeon, for example, did not mention what the side effects would be of stopping HRT prior to surgery."I would not have changed my mind about having surgery, it is true, but I could have done more to prepare had I known about the impact of ceasing hormone replacement therapy," they wrote:Knowing in advance is crucial to psychological preparation and adaptation. Armed with knowledge, I could have scheduled appointments with my therapist, warned my loved ones about my increased need for support and softness, and refrained from in-person commitments. I did the latter two of those for a subsequent surgical procedure. Claim: "An article published in a medical journal makes reference to nicknames for hormone replacement therapy that included ""antiboyotics, trans-mission fluid, and the Notorious H.R.T."

Ex Output:
Did a Medical Journal List 'The Notorious H.R.T.' as a Nickname for Hormone Replacement Therapy?